About: How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support
Creator	Streja, Elani Attai, Deanna Baker, Jennifer Berkowitz, Jacob Berkowitz, Maurice Lee, Minna Thompson, Carlie Zibecchi, Laura Cachet, & Dinome, Maggie Wenziger, M
Source	Medline; PMC
abstract	PURPOSE: Many patients with hormone receptor–positive (HR+) breast cancer do not adhere to endocrine therapy (ET), and treatment-related side effects are often discussed by participants in online breast cancer forums. Our aim was to survey this unique group of patients about their ET-related experiences. METHODS: We partnered with patients active in breast cancer social media communities to develop a survey assessing ET-related side effects and medical team communication. Patients with a history of HR+ breast cancer who had received a recommendation to take ET were eligible to participate in the anonymous, online survey. RESULTS: Respondents included 2353 women and 54 men. Aromatase inhibitors were the most commonly used medication. Side effects were reported by 91.2%, were more often experienced by women than men (p < 0.001), and were primarily related to medication type. Approximately one-third of respondents discontinued therapy early. While most felt supported by their medical team, 31.5% reported that their side effects were dismissed or minimized. Survey respondents most frequently reported that a healthy diet and exercise, yoga/acupuncture, and vitamins/supplements were helpful in managing ET-related side effects. CONCLUSIONS: ET-related side effects are very common, and one-third discontinued treatment early. Lifestyle changes and complementary therapies can be important tools for side effect management. One-third of patients did not feel that their side effects were taken seriously. IMPLICATIONS FOR CANCER SURVIVORS: This is the largest survey of ET use by participants in online breast cancer communities. Further research is needed to identify strategies to improve treatment adherence and to better manage ET-related side effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11764-020-00908-5) contains supplementary material, which is available to authorized users.
has issue date	2020-08-17(xsd:dateTime)
bibo:doi	10.1007/s11764-020-00908-5
bibo:pmid	32804353
has license	no-cc
sha1sum (hex)	7559fa188d87ce8b0eea469a8d65eda6fb8c4c8c
schema:url	https://doi.org/10.1007/s11764-020-00908-5
resource representing a document's title	How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support
has PubMed Central identifier	PMC7430212
has PubMed identifier	32804353
schema:publication	J Cancer Surviv
resource representing a document's body	covid:7559fa188d87ce8b0eea469a8d65eda6fb8c4c8c#body_text
is schema:about of	named entity 'forums' named entity 'Side effects' named entity 'management' named entity 'manage' named entity 'side effects' named entity 'therapy' named entity 'IMPORTANT' named entity 'VITAMINS' named entity 'OUR' named entity 'COMPLEMENTARY THERAPIES' named entity 'MANAGE' named entity 'STRATEGIES' named entity 'LIFESTYLE CHANGES' named entity 'survey' named entity 'type' named entity 'vitamins' named entity 'medication' named entity 'experiences' named entity 'breast cancer' named entity 'Survey' named entity 'received' named entity 'breast cancer' named entity 'endocrine' named entity 'unique' named entity 'dismissed' named entity 'participate' named entity 'develop' named entity 'minimized' named entity 'How' named entity 'therapy' named entity 'breast cancer' named entity 'endocrine therapy' named entity 'treatment adherence' named entity 'social media' named entity 'medical team' named entity 'endocrine therapy' named entity 'group' named entity '13.0' named entity 'concomitant therapy' named entity 'medication adherence' named entity 'quality of life' named entity 'men with breast cancer' named entity 'nutrition' named entity 'COVID-19 pandemic' named entity 'male breast cancer' named entity 'myocardial infarction' named entity 'medical marijuana' named entity 'tamoxifen' named entity 'social media' named entity 'medical care' named entity 'social media' named entity 'complementary therapies' named entity 'Facebook' named entity 'tamoxifen' named entity 'gender reassignment' named entity 'peer support' named entity 'chronic conditions' named entity 'high-risk' named entity 'recall bias' named entity 'Dr. Susan Love' named entity 'tamoxifen' named entity 'socioeconomic status' named entity 'quality of life' named entity 'physical therapy' named entity 'general health' named entity 'hypertension' named entity 'socioeconomic status' named entity 'social worker' named entity 'arthralgia' named entity 'Effect modification' named entity 'exemestane'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software